Award
NIH Reporter #5R01CA262420-04
SLC6A14 as a unique drug target to treat pancreatic cancer
Recipient
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
Award Amount
$349,640.00
Ceiling
$349,640.00
Awarded
April 10, 2026
Identifier
5R01CA262420-04
Award for research on SLC6A14 as a drug target to treat pancreatic cancer, funded by the National Cancer Institute with a total cost of $349,640 for fiscal year 2026, project duration May 2026 to April 2028.
Description
This project involves evaluating SLC6A14 as a drug target for pancreatic ductal adenocarcinoma (PDAC), characterizing autophagy and macropinocytosis induced by SLC6A14 inactivation, and testing combination therapies targeting SLC6A14 and autophagy/macropinocytosis.